Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10788154 | 0.86 | PSMD14 (0.36) | TSHRMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL12971136 | 0.84 | MAPT (0.36) | MAPTHPGDTSHRMEN1KMT2A | |
| SCHEMBL2182038 | 0.79 | TP53 (0.33) | MAPTHPGDTSHRMEN1KMT2A | |
| SCHEMBL25359833 | 0.79 | MEN1 (0.45) | MAPTHPGDTSHRMEN1KMT2A | |
| SCHEMBL152413 | 0.79 | — | — | |
| SCHEMBL16752050 | 0.77 | — | — | |
| SCHEMBL8847331 | 0.77 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL16752011 | 0.76 | — | — | |
| SCHEMBL16752091 | 0.76 | — | — | |
| SCHEMBL8848705 | 0.76 | KIF11 (0.39) | MAPTHPGDTSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3827063-A1 | FAST CURING EPOXY ACRYLIC LIQUID SHIM | Henkel IP & Holding GmbH (DE) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020023292-A1 | FAST CURING EPOXY ACRYLIC LIQUID SHIM | Henkel IP & Holding GmbH (DE) | 2020-01-30 | — | — | WO | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2176355-A1 | THERMOSET DAMPENER MATERIAL | Dow Global Technologies Inc. (US) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009018194-A1 | THERMOSET DAMPENER MATERIAL | DOW GLOBAL TECHNOLOGIES INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-0566536-A1 | Electrically conducting polymer compositions and their use | Japat Ltd (CH) | 1993-10-20 | — | — | EP | disclosed |
| EP-0563013-A2 | N-substituted chitosane derivatives, process for preparing them and their use | CIBA-GEIGY AG (CH) | 1993-09-29 | — | — | EP | disclosed |
| EP-0321595-A1 | Fiber reinforced thermosetting resin composition with coated fibers for improved toughness | AMERICAN CYANAMID COMPANY (US) | 1989-06-28 | — | — | EP | disclosed |
| US-4142034-A | Epoxy resin compositions containing an amine-cyanic acid ester combination curing agent | CINCINNATI MILACRON INC. (US) | 1979-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | MAPT 4229/4885HPGD 3598/4885TSHR 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.